Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints. Th ...

Cracked heels are a common problem, especially with age. Thinning fat pads and drier skin contribute to this. Friction, ...

Everyone’s talking about hypochlorous acid sprays. Here’s how to use it without sabotaging your skin-care routine.

Smoking's detrimental effects extend far beyond lungs, severely impacting skin health. The habit accelerates ageing, causing ...

XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | FSE: ANU), a late-stage clinical pharmaceutical company, pivoted to ...

PureWow editors select every item that appears on this page, and some items may be gifted to us. Additionally, PureWow may ...

Discover Protagonist Therapeutics’ latest breakthroughs in hematology and immunology drugs, market opportunities, and R&D insights from the 2025 ...

From cult-favorite body creams to machine-washable Mary Jane flats and travel-ready duffle bags that’s won’t ruin your outfit ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Jason Chen Jason Chen is an editor overseeing Wirecutter’s tech and home ...

Johnson & Johnson has also initiated the Phase 3 ICONIC-ASCEND f study, the first head-to-head study seeking to demonstrate the superiority of an oral tablet, icotrokinra, compared to an injectable ...